Main products & Service

1. Next generation diagnostics for “Mycoplasma Infectious Diseases”

Stage: Service/Marketing.

Outline: Trust measurement of the precise amount of antibodies in sera, to discover effective, advanced-medicine to create superior outcomes for patients.
・The novel diagnostic method could be used to measure IgM, IgG, and IgA, separately. And it make appropriate medical treatment possible.
・The medical treatment – traditional/complementary/orthomolecular/alternative/comprehensive/holistic/integrated therapies.

Milestone: We are seeking partnering opportunities in and create global network such as clinical diagnosis, research institute, hospitals for the therapy of mycoplasma infectious diseases.

 2. Vaccine for “Mycoplasma Infectious Diseases”

Stage: Development

Outline: Simplest component vaccine, whose component are chemically-synthesized lipid-antigens.
・Ultimately Safer vaccine without Adjuvant, cell culture.
・Liposome induces specific antibodies. GLP liposome could be prepared.

Milestone: We are seeking a co-development and marketing partner of mycoplasma vaccine in the pharmaceutical companies and biotech industries world wide. IND, preclinical～PhI/PhII, PhIII and marketing. Also we are seeking for $ 20M investment or fund for pre-clinical～PhI/PhII

 3. Therapeutic antibodies, adjuvant, and new drug design.

Stage: Service/Development

・Expand for application of drugs for “Mycoplasma Infectious Diseases”
・Research: PhIII and marketing, PhIV differential diagnosis of side effects (interstitial pneumonia, Stevens-Johnson syndrome) .
・Immunomodulation interplay between innate and adaptive immunity, and novel T and B cell mechanism.

Milestone: We are seeking a mutual relationship for co-development of new therapeutic drugs with pharmaceutical industries using mycoplasma companion diagnostics.